Cargando…

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma – a phase II study

Detalles Bibliográficos
Autores principales:	Morschhauser, Franck, Bouabdallah, Kamal, Stilgenbauer, Stephan, Thieblemont, Catherine, de Guibert, Sophie, Zettl, Florian, Gelbert, Lawrence M., Turner, P. Kellie, Kambhampati, Siva Rama Prasad, Li, Li, Li, Lily Q., Buchanan, Sean, Barriga, Susana, Bear, Melissa M., Wilhelm, Martin, Hess, Georg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927997/ https://www.ncbi.nlm.nih.gov/pubmed/32381571 http://dx.doi.org/10.3324/haematol.2019.224535

Ejemplares similares

Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics
por: Chigutsa, Emmanuel, et al.
Publicado: (2020)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
por: Kirschey, Sebastian, et al.
Publicado: (2012)

Abemaciclib does not increase the corrected QT interval in healthy participants
por: Chappell, Jill C., et al.
Publicado: (2023)

Abemaciclib for breast cancer
Publicado: (2020)

P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
por: Sarkozy, Clementine, et al.
Publicado: (2023)

Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma
por: Lisson, Catharina Silvia, et al.
Publicado: (2022)

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
por: Arcaini, Luca, et al.
Publicado: (2017)

Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate
por: Chappell, Jill C., et al.
Publicado: (2018)

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
por: Torres-Guzmán, Raquel, et al.
Publicado: (2017)

Mantle Cell Lymphoma Relapsing at the Lymphedematous Arm
por: Massini, Giuseppina, et al.
Publicado: (2013)

Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats
por: Sun, Sen, et al.
Publicado: (2022)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Abemaciclib: A multi-functional radiation modifier
por: Naz, Sarwat, et al.
Publicado: (2019)

A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
por: Tate, Sonya C., et al.
Publicado: (2017)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
por: Bouard, Louise, et al.
Publicado: (2022)

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
por: Johnston, Stephen, et al.
Publicado: (2019)

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023)

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
por: Dreyling, M., et al.
Publicado: (2017)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
por: Le Gouill, Steven, et al.
Publicado: (2023)

Profile of abemaciclib and its potential in the treatment of breast cancer
por: Martin, James M, et al.
Publicado: (2018)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report
Publicado: (2020)

Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
por: Mitarai, Yuki, et al.
Publicado: (2022)

Clinicoradiological course of abemaciclib-induced pneumonitis with histology findings
por: Okayasu, Kaori, et al.
Publicado: (2023)

An experimental study: the effect of S. boulardii on abemaciclib-induced diarrhea
por: CAKCAK, İbrahim Ethem, et al.
Publicado: (2022)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
por: Rule, Simon A., et al.
Publicado: (2019)

Molecular docking and machine learning analysis of Abemaciclib in colon cancer
por: Liñares-Blanco, Jose, et al.
Publicado: (2020)

Efficacy of Abemaciclib in the Management of Refractory Metastatic Extramammary Paget’s Disease
por: Takahashi, Gary W, et al.
Publicado: (2022)

Are you treating ypN0 patient with adjuvant abemaciclib?
por: Toss, A., et al.
Publicado: (2023)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Relapsed Mantle Cell Lymphoma Presenting as “Sister Mary Joseph Nodule”
por: Vaughn, Jennifer E., et al.
Publicado: (2010)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
por: Aydilek, Enver, et al.
Publicado: (2023)

Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis
por: Hess, Georg, et al.
Publicado: (2015)

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling
por: Posada, Maria M., et al.
Publicado: (2020)

Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group
por: Bonnet, Christophe, et al.
Publicado: (2022)

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments
por: Nawa, Hideki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tj940njgiqvorbm23hvkf99ql5